Sustained and long-term release of doxorubicin from plga nanoparticles for eliciting anti-tumor immune responses

HIGHLIGHTS

  • who: Jeongrae Kim and collaborators from the Graduate School of Converging Science and Technology, Korea University, Anam-ro have published the Article: Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses, in the Journal: Pharmaceutics 2022, 14, 474. of 28/01/2022
  • what: The primary reason of this reduced cytotoxicity of DOX from DP-NPs was its sustained-release property.
  • how: These results were analyzed using FlowJoTM software (BD Biosciences NJ USA).

SUMMARY

    All these features and behaviors of DP-NPs were . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?